PPIG and metabolic syndrome: The CYP3A4 inhibition propensity of silibinin in comparison with that of recommended (non-3A4 substrates such as rosuvastatin) and non-recommended (3A4 substrates such as simvastatin) statins to clinically manage lorlatinib-associated dyslipidemia was initially predicted using the DL-CYP prediction server [39], a free web tool to evaluate the tendency of small molecules to inhibit five major CYP450 isoforms (1A2, 3C9, 2C19, 2D6, and 3A4).